&nbsp;

ICCU-Cannabis-Poster-fr_AODA.pdf

New

May 2025

Document

ICCU-Vaping-Poster_AODA-fr.pdf

New

May 2025

Document

Inuit-Depistage-du-cancer-du-sein.pdf

New

Jun 2025

Document

Inuit-Depistage-cancer-du-col-de-luterus.pdf

New

Jun 2025

Document

Inuit-Depistage-du-cancer-colorectal.pdf

New

Jun 2025

Document

Inuit-Depistage-cancer-du-poumon.pdf

New

Jun 2025

Drug

ipilimumab

Other Name(s): Yervoy®

Quick Link(s): Drug Monograph, Patient Info Sheet

Aug 2024

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Palliative

Drugs Used:

iBRUtinib (Unfunded)